rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Illumina, Inc.

ILMN · Nasdaq

Health CareLife-science toolsLeadingSynthetic Biology / TechBio

ILMN stood above a rising 150-day average in 52 of the last 52 weekly readings, every one of them. It is 45.8% above that average now. Life Science Tools & Research Services: 52% of its 79 stocks in an uptrend (+1 points in four weeks); Health Care: 28% (−9 points in four weeks).

Statistics

Rotation
Leading
Weeks in an uptrend
52 in a row
Industry in uptrend
52% +1 in 4 wk
Insider buys, 12 months
$108K
Insider sales, 12 months
$1.2B
Officials’ trades on record
56
Institutions holding
878 (+85)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 52 of 52 weeks.

21 Apr – 20 Oct
27%44%61%Apr 26Jun 26Jul 26Sep 26Oct 26

Life-science tools: About half its stocks are in an uptrend and the share has held steady. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$731.0M$0Nov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

56 disclosed lines: House 47, Senate 2, executive 7; 17 people.

WhoDidAmountTraded
Donald J. Trump Executive branch: Office of Government EthicsWhite House Officebought$1k–$15k15 Apr 2026filed 1 Jul 2026
Donald J. Trump Executive branch: Office of Government EthicsWhite House Officebought$1k–$15k7 Apr 2026filed 1 Jul 2026
Gilbert Ray Cisneros, Jr. House: U.S. House ClerkCA31bought$1k–$15k10 Feb 2026filed 9 Mar 2026
Lisa C. McClain House: U.S. House ClerkMI09soldspouse$1k–$15k31 Oct 2025filed 21 Nov 2025
Lisa C. McClain House: U.S. House ClerkMI09soldspouse$1k–$15k30 Oct 2025filed 21 Nov 2025
Lisa C. McClain House: U.S. House ClerkMI09boughtspouse$1k–$15k30 Oct 2025filed 21 Nov 2025
Lisa C. McClain House: U.S. House ClerkMI09boughtspouse$1k–$15k9 Jun 2025filed 13 Aug 2025
Thomas H. Kean, Jr. House: U.S. House ClerkNJ07bought$1k–$15k1 Apr 2025filed 15 May 2025
Thomas H. Kean, Jr. House: U.S. House ClerkNJ07bought$1k–$15k1 Apr 2025filed 18 Apr 2025
Michael C. Burgess House: U.S. House ClerkTX26soldspouse$15k–$50k3 Sep 2024filed 24 Sep 2024
Michael C. Burgess House: U.S. House ClerkTX26sold$15k–$50k30 Aug 2024filed 1 Oct 2024
Thomas H. Kean, Jr. House: U.S. House ClerkNJ07bought$1k–$15k19 Apr 2024filed 30 May 2024

Insiders

Buy orders, 12 months2
Sale orders, 12 months29
Buyers · sellers1 · 5
WhoDidSharesTraded
Keith A. MeisterDirectorsold7,500at $217.284 Sep 2026filed 4 Sep 2026
Keith A. MeisterDirectorsold100,650at $218.394 Sep 2026filed 4 Sep 2026
Keith A. MeisterDirectorsold11,351at $219.184 Sep 2026filed 4 Sep 2026
Keith A. MeisterDirectorsold8,439at $215.203 Sep 2026filed 4 Sep 2026
Keith A. MeisterDirectorsold13,261at $216.383 Sep 2026filed 4 Sep 2026
Keith A. MeisterDirectorsold14,196at $217.293 Sep 2026filed 4 Sep 2026
Keith A. MeisterDirectorsold9,721at $218.333 Sep 2026filed 4 Sep 2026
Keith A. MeisterDirectorsold13,717at $219.413 Sep 2026filed 4 Sep 2026
Keith A. MeisterDirectorsold6,656at $220.173 Sep 2026filed 4 Sep 2026
Keith A. MeisterDirectorsold9,961at $221.553 Sep 2026filed 4 Sep 2026
Keith A. MeisterDirectorsold57,488at $213.202 Sep 2026filed 4 Sep 2026
Keith A. MeisterDirectorsold10,620at $213.732 Sep 2026filed 4 Sep 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders878+85 on the quarter
New · exited159 · 73
Reported value$27.0B

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
BlackRock, Inc.added · filed 7 Aug 202619,191,398$3.4B+167,808+0.9%
Capital World Investorsreduced · filed 12 Aug 202615,425,298$2.7B-124,662−0.8%
VANGUARD PORTFOLIO MANAGEMENT LLCreduced · filed 13 Aug 20266,627,157$1.2B-196,497−2.9%
VANGUARD CAPITAL MANAGEMENT LLCreduced · filed 13 Aug 20266,587,534$1.2B-7,302−0.1%
STATE STREET CORPadded · filed 7 Aug 20266,507,288$1.1B+77,944+1.2%
WCM INVESTMENT MANAGEMENT, LLCadded · filed 13 Aug 20266,206,701$1.1B+283,528+4.8%
FMR LLCadded · filed 13 Aug 20264,523,417$795.4M+2,976,556+192.4%
AQR CAPITAL MANAGEMENT LLCreduced · filed 14 Aug 20263,544,465$623.2M-436,615−11.0%
PRIMECAP MANAGEMENT COadded · filed 14 Aug 20263,514,649$618.0M+1,447,350+70.0%
GEODE CAPITAL MANAGEMENT, LLCreduced · filed 12 Aug 20262,946,669$516.7M-104,610−3.4%
31 Mar 2023 – 30 Jun 2026
659765870Mar 23Dec 23Dec 24Sep 25Jun 26

Everyone who traded it

Jacob Thaysen Company insiderChief Executive Officer · last 5 Oct 20263 · 0
Keith A. Meister Company insiderDirector · last 30 Sep 20260 · 16
Scott B. Ullem Company insiderDirector · last 30 Sep 20260 · 0
Julie Ann Coletti Company insiderChief Legal Officer · last 8 Sep 20260 · 0
Steven Barnard Company insiderSVP, Chief Technology Officer · last 5 Sep 20260 · 0
Christensen Jakob Wedel Company insiderSVP, Strategy/Corp Development · last 18 Aug 20260 · 3
Michael C. Sullivan Company insiderChief Commercial Officer · last 5 Aug 20260 · 0
Scott M. Davies Company insiderChief Legal Officer · last 30 Jul 20260 · 5
Daniel Skovronsky Company insiderDirector · last 16 Jun 20260 · 0
Patricia Leckman Company insiderSVP, Chief People Officer · last 5 Jun 20260 · 3
Scott D. Ericksen Company insiderVP, Chief Accounting Officer · last 29 May 20260 · 2
Anna Richo Company insiderDirector · last 21 May 20260 · 0

Same industry

OABI OmniAbLeading+75%
TXG 10x GenomicsLeading+61%
AVTR AvantorLeading+48%
RVTY RevvityLeading+39%
MASS 908 DevicesLeading+32%

Distance from each stock’s own 150-day average.

From its SEC filings

Profit per saleFY 2025 · to 28 Dec 202566.1%
Operating profit marginFY 2025 · to 28 Dec 202518.6%
Free cash flow marginFY 2025 · to 28 Dec 202521.4%
Return on capital employedFY 2025 · to 28 Dec 202516.0%
Cash conversionFY 2025 · to 28 Dec 2025127%
Research spendFY 2025 · to 28 Dec 202522.3%
Share count trendFY 2025 · to 6 Feb 2026-0.1%
Cash and equivalentsFY 2025 · to 28 Dec 2025$1.4B
Free cash flowFY 2025 · to 28 Dec 2025$931.0M

Analyst forecasts

No analyst forecasts yet.